NEWS RELEASE
APH:TSX-V APCSF:OTCQB January 5, 2012
ALDA reschedules Annual General and Special Meeting for January 27, 2012
Vancouver, BC - ALDA Pharmaceuticals Corp. (APH:TSX-V) (the
"Company" or "ALDA") announces that it has changed the date
of its Annual General and Special Meeting (the "Meeting")
from January 23, 2012, to January 27, 2012, and proposes to
set the number of Directors at five, elect its Board of
Directors, appoint the auditor and approve the Stock Option
Plan.
In addition, a consolidation of ALDA's common shares will be
proposed. The Company currently has
63,996,799 common shares outstanding. ALDA proposes to
consolidate its common shares such that one (1) new common
share would be issued for every twenty (20) old common shares
outstanding, or such lower consolidation ratio as may be
determined by the directors of ALDA. If the share
consolidation is completed on a 20 to 1 basis, ALDA would
have approximately 3,199,840 post- consolidated common shares
outstanding. The proposed share consolidation is subject to
the approval of the TSX Venture Exchange and by a 75% vote in
favour by the shareholders of ALDA. Management supports the
completion of a share consolidation to facilitate future
financings which would be accomplished through the issuance
of common shares. Without future financings, ALDA may be
moved from Tier II to NEX.
The Company also announces that the appointment of Mr. Sina
Pirooz to the Board of Directors of the Company, as announced
on December 18, 2011, has not been completed due to the
proposal to reduce the number of Directors at the Meeting
from six to five due to the resignation of Mr. Eugene Hodgson
on December 15, 2011.
Further details on the Meeting are contained in the Company's
Information Circular posted on under the
Company's profile at www.sedar.com.
Terrance Owen
President & CEO
ALDA Pharmaceuticals Corp.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-looking Statements: Information in this press release that involves ALDA's expectations, plans, intentions or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. ALDA generally uses words such as "outlook," "will," "could," "would," "might," "remains," "to be," "plans," "believes," "may," "expects," "intends," "anticipates," "estimate," "future," "plan," "positioned," "potential," "project," "remain," "scheduled," "set to," "subject to," "upcoming," and similar expressions to help identify forward-looking statements. The forward-looking statements in this release are based upon information available to ALDA as of the date of this release, and ALDA assumes no obligation to update any such forward- looking statements. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These
ALDA Pharmaceuticals Corp.
Telephone [604] 521.8300 - Facsimile [604] 521.8322
www.aldacorp.com
statements are not guarantees of the future performance of ALDA and are subject to risks, uncertainties and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations.
ALDA Pharmaceuticals Corp.
Telephone [604] 521.8300 - Facsimile [604] 521.8322
www.aldacorp.com
distribué par | Ce noodl a été diffusé par ALDA Pharmaceuticals Corp. et initialement mise en ligne sur le site http://www.aldacorp.com. La version originale est disponible ici. Ce noodl a été distribué par noodls dans son format d'origine et sans modification sur 2012-01-06 20:01:40 PM et restera accessible depuis ce lien permanent. Cette annonce est protégée par les règles du droit d'auteur et toute autre loi applicable, et son propriétaire est seul responsable de sa véracité et de son originalité. |
Documents associés | |
ALDA reschedules Annual General and Special Meeting for January 27, 2012 |